CA2652981A1 - Formulations robustes a liberation prolongee - Google Patents

Formulations robustes a liberation prolongee Download PDF

Info

Publication number
CA2652981A1
CA2652981A1 CA002652981A CA2652981A CA2652981A1 CA 2652981 A1 CA2652981 A1 CA 2652981A1 CA 002652981 A CA002652981 A CA 002652981A CA 2652981 A CA2652981 A CA 2652981A CA 2652981 A1 CA2652981 A1 CA 2652981A1
Authority
CA
Canada
Prior art keywords
sustained release
release formulation
drug
opioid
gum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002652981A
Other languages
English (en)
Other versions
CA2652981C (fr
Inventor
Anand R. Baichwal
Kevin Fitzmaurice
Steve Labudzinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penwest Pharmaceuticals Co
Original Assignee
Penwest Pharmaceuticals Co.
Anand R. Baichwal
Kevin Fitzmaurice
Steve Labudzinski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co., Anand R. Baichwal, Kevin Fitzmaurice, Steve Labudzinski filed Critical Penwest Pharmaceuticals Co.
Publication of CA2652981A1 publication Critical patent/CA2652981A1/fr
Application granted granted Critical
Publication of CA2652981C publication Critical patent/CA2652981C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2652981A 2006-10-10 2006-10-10 Formulations robustes a liberation prolongee Expired - Fee Related CA2652981C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/039923 WO2008045060A1 (fr) 2006-10-10 2006-10-10 Formulations robustes à libération prolongée

Publications (2)

Publication Number Publication Date
CA2652981A1 true CA2652981A1 (fr) 2008-04-17
CA2652981C CA2652981C (fr) 2012-05-01

Family

ID=38048029

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2652981A Expired - Fee Related CA2652981C (fr) 2006-10-10 2006-10-10 Formulations robustes a liberation prolongee

Country Status (10)

Country Link
EP (1) EP2079453A1 (fr)
JP (1) JP5422388B2 (fr)
KR (1) KR20090113243A (fr)
CN (1) CN101578096A (fr)
AU (1) AU2006349402A1 (fr)
BR (1) BRPI0621947A2 (fr)
CA (1) CA2652981C (fr)
IL (1) IL198168A0 (fr)
MX (1) MX2009003771A (fr)
WO (1) WO2008045060A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219478T2 (de) 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
CA2839123A1 (fr) 2011-07-29 2013-02-07 Grunenthal Gmbh Comprime anti-manipulation permettant une liberation immediate de medicament
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
WO2013156453A1 (fr) 2012-04-18 2013-10-24 Grünenthal GmbH Forme pharmaceutique inviolable et résistante à la libération massive
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
JP2017516789A (ja) * 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
CN104622791A (zh) * 2015-02-13 2015-05-20 扬子江药业集团有限公司 地佐辛口服制剂
CA2998259A1 (fr) 2015-09-10 2017-03-16 Grunenthal Gmbh Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
US20170296476A1 (en) * 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
KR102380498B1 (ko) * 2021-02-24 2022-04-01 주식회사 청안오가닉스 건강기능식품에 있어서 유효성분의 지속적인 방출을 제어할 수 있는 서방형 정제를 제조하기 위한 조성물
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
OA11926A (en) * 1999-04-13 2006-04-12 Beecham Pharmacueticals Pte Lt Novel method of treatment
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
ATE376832T1 (de) * 2001-07-06 2007-11-15 Penwest Pharmaceuticals Co Verzögert freisetzende formulierungen von oxymorphon
DE60219478T2 (de) * 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
CA2459976A1 (fr) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives
WO2006094083A1 (fr) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Formulations de venlafaxine a liberation controlee

Also Published As

Publication number Publication date
AU2006349402A1 (en) 2008-04-17
MX2009003771A (es) 2009-07-22
CN101578096A (zh) 2009-11-11
CA2652981C (fr) 2012-05-01
IL198168A0 (en) 2009-12-24
BRPI0621947A2 (pt) 2011-10-18
WO2008045060A1 (fr) 2008-04-17
EP2079453A1 (fr) 2009-07-22
JP2010505949A (ja) 2010-02-25
KR20090113243A (ko) 2009-10-29
JP5422388B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
CA2652981A1 (fr) Formulations robustes a liberation prolongee
AU2002337686B2 (en) Opioid formulations having reduced potential for abuse
KR101408315B1 (ko) 다층 경구 붕해 정제
CA2699172C (fr) Compositions et methodes de distribution de medicaments peu solubles
HRP20100289T1 (hr) Proizvodi otporni na miješanje za opioidnu primjenu
CA2519556A1 (fr) Forme posologique inviolable contenant des particules co-extrudees d'agent repulsif contraire et procede de fabrication
HRP20120641T1 (hr) Oralni farmaceutski oblici doziranja otporni na neovlašteno korištenje koji sadrže opioidni analgetik
CA2640339A1 (fr) Formulations de dosage d'opioides infalsifiables
US20020164373A1 (en) Opioid sustained-released formulation
JP2009529046A5 (fr)
HRP20150835T1 (hr) Farmaceutski oblici doziranja s kontroliranim oslobađanjem
CA2557839A1 (fr) Forme posologique resistant aux violations, comprenant un absorbant et un agent adverse
AU2002337686A1 (en) Opioid formulations having reduced potential for abuse
CA2913368A1 (fr) Formulation a liberation immediate empechant les utilisations abusives
EP1981502A2 (fr) Préparation pharmaceutique contenant: un agoniste opioïde central, un antagoniste opioïde central, et un antagoniste opioïde périphérique, et sa méthode d'obtention
HRP20210973T1 (hr) Farmaceutske kompozicije otporne na zlouporabu
AU2018232854B2 (en) Novel dosage form
HRP20141001T1 (hr) Farmaceutski sferoidi
CA2446639A1 (fr) Composition prevenant la toxicomanie dans le soulagement de la douleur
US20160256451A1 (en) Dosage of naloxone
WO2018235104A2 (fr) Forme pharmaceutique solide orale dissuasive d'abus
AU2016266061A1 (en) Particulate Compositions for Delivery of Poorly Soluble Drugs
AU2014277657A1 (en) Particulate Compositions for Delivery of Poorly Soluble Drugs

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201013